SCHEMBL8513611

SCHEMBL8513611

Cn1c2ccccc2c2nc3nc(Nc4ccccc4)ncc3c(=O)n21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WEE1 P30291 4/20 0.47
CYP1A2 P05177 8/20 0.47
CYP3A4 P08684 4/20 0.47
CYP2C9 P11712 3/20 0.47
CYP2D6 P10635 1/20 0.47
USP2 O75604 5/20 0.46
CDK4 P11802 5/20 0.46
CCND3 P30281 5/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
CCND1 P24385 4/20 0.46
CCND2 P30279 4/20 0.46
CYP2C19 P33261 3/20 0.46
TSHR P16473 3/20 0.46
MAPK1 P28482 1/20 0.46
CASP1 P29466 3/20 0.46
CASP7 P55210 3/20 0.46
GSK3B P49841 2/20 0.46
HIF1A Q16665 2/20 0.46
GSK3A P49840 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8513247 0.86 LCK (0.54) WEE1CYP3A4CDK4CCND3CCND1
SCHEMBL8513578 0.82 WEE1 (0.41) WEE1CYP1A2CYP3A4CYP2C9CYP2D6
SCHEMBL8510401 0.81 TNK2 (0.51) WEE1SRC
SCHEMBL8510422 0.79 WEE1 (0.51) WEE1SRC
SCHEMBL13174805 0.79 WEE1 (0.45) WEE1CDK4CCND3CCND1CCND2
SCHEMBL188721 0.78 MEN1 (0.44) CYP1A2USP2MEN1KMT2ATSHR
SCHEMBL8510675 0.77 WEE1 (0.47) WEE1FGFR1SRC
SCHEMBL214554 0.75 WEE1 (0.53) WEE1CYP3A4CDK4CCND3CCND1
SCHEMBL216994 0.75 WEE1 (0.48) WEE1
SCHEMBL8514433 0.74 WEE1 (0.53) WEE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288396-B2 Pyrimidopyrimidoindazole derivative MSDKK (JP) 2012-10-16 US disclosed
US-8288396-B2 Pyrimidopyrimidoindazole derivative MSDKK (JP) 2012-10-16 US disclosed
US-8288396-B2 Pyrimidopyrimidoindazole derivative MSDKK (JP) 2012-10-16 US disclosed
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-05-31 US disclosed
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-05-31 US disclosed
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-05-31 US disclosed
WO-2010098367-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE WEE1, WEE2, DCK WEE1 1/4885CYP1A2 1318/4885CYP3A4 1752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.